Zobrazeno 1 - 6
of 6
pro vyhledávání: '"R J, Barren"'
Autor:
R J, Barren, E H, Holmes, A L, Boynton, A, Gregorakis, A A, Elgamal, O E, Cobb, C L, Wilson, H, Ragde, G P, Murphy
Publikováno v:
The Prostate. 36(3)
Prostate-specific antigen (PSA) cannot differentiate benign prostatic hyperplasia (BPH), from prostatitis, or prostate cancer in the range of 4.0-10 ng/ml. An accurate cytologic or histologic assessment is necessary to confirm the proper diagnosis. T
Autor:
G P, Murphy, R T, Maguire, B, Rogers, A W, Partin, W B, Nelp, M J, Troychak, H, Ragde, G M, Kenny, R J, Barren, V A, Bowes, A K, Gregorakis, E H, Holmes, A L, Boynton
Publikováno v:
The Prostate. 33(4)
Stored serum from clinical trial cases undergoing ProstaScint (CYT-356) scanning were available for Prostate Specific Membrane Antigen (PSMA) assay. Prostate Specific Antigen (PSA) levels had already been determined. This provided an opportunity to s
Autor:
G P, Murphy, M J, Troychak, O E, Cobb, V A, Bowes, R J, Kenny, R J, Barren, G M, Kenny, H, Ragde, E H, Holmes, R L, Wolfert
Publikováno v:
The Prostate. 33(2)
Metastatic prostate cancer clinical evaluation is difficult. A revaluation of new prostate markers with regard to bone scans was performed.Serial markers, including bone alkaline phosphatase (BAP), total alkaline phosphatase (TAP), prostate-specific
Publikováno v:
The Prostate. 30(1)
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein defined by the monoclonal antibody 7E11.C5. The 7E11.C5 antibody forms the basis of an in vivo diagnostic imaging agent (ProstaScint, Cyt-356) for identification of metastatic
Autor:
G P, Murphy, W T, Tino, E H, Holmes, A L, Boynton, S J, Erickson, V A, Bowes, R J, Barren, B A, Tjoa, S L, Misrock, H, Ragde, G M, Kenny
Publikováno v:
The Prostate. 28(4)
Work to date has identified prostate-specific membrane antigen (PSMA) as a membrane-bound glycoprotein with high specificity for prostatic epithelial cells. PSMA reacts with the monoclonal antibody 7E11.C5, which is present in serum, seminal fluid, a
Publikováno v:
Clinical Nuclear Medicine. 18:810